Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Research Priorities: A Taste Of What's To Come?

This article was originally published in RPM Report

Executive Summary

Any government-sponsored center on comparative effectiveness will focus on the research priorities of the Medicare and Medicaid programs as a way to lower health care costs. The findings of a Medicare coverage advisory committee offers a glimpse of where those priorities may fall.

You may also be interested in...



The Devil is in the Details: CMS To Flesh Out Committee's Research Role

CMS plans to be more open about how the Medicare coverage advisory committee will score research priorities after comments from industry. Stakeholders know the process won't any easier after Election Day.

The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness

A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.

Show Me the Value

As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.

Topics

UsernamePublicRestriction

Register

PS080399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel